PharmiWeb.com - Global Pharma News & Resources

Press Releases - 2024-09-09

Date Title Company
09-Sep-2024 BioNxt Receives Positive International Examination Report From the European Patent Office for Broad Patent Application for Sublingual Delivery of Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases AccessWire
09-Sep-2024 Abivax presents first-half 2024 financial results ABIVAX
09-Sep-2024 Champions Oncology to Announce First Quarter Financial Results on Wednesday, September 11, 2024 AccessWire
09-Sep-2024 CELLTech(TM) DBS: Your Brain’s Healing Power Under Your Control AccessWire
09-Sep-2024 iCardio.ai and SARC MedIQ PACS Partner to Revolutionize Ultrasound Interpretation With AI Tools AccessWire
09-Sep-2024 Pierre Fabre Laboratories receives European Commission Approval for BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAFV600E mutation Pierre Fabre Laboratories
09-Sep-2024 Deafblind UK is proud to announce its highly anticipated 2024 conference, ‘Standing Out and Fitting In’, set to take place online on the 3 October 2024. Deafblind UK
09-Sep-2024 AstraZeneca announces the completion of the clinical programme to support the transition of Breztri to next-generation propellant with near-zero Global Warming Potential AstraZeneca
09-Sep-2024 The OTL Group toasts 40 years of success OTL Group
09-Sep-2024 TILT Biotherapeutics Presents Clinical Data on TILT-123 After Fully Intravenous Delivery Regimen at ESMO 2024 TILT Biotherapeutics
09-Sep-2024 Anocca Presents Data at ESMO Congress on Preclinical Development of its TCR-T Cell Therapies for Cancer Anocca
09-Sep-2024 HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer HUTCHMED
09-Sep-2024 Transgene and BioInvent to Present Promising Initial Phase I/IIa Data on Oncolytic Virus, BT-001, at ESMO 2024 Transgene and BioInvent
09-Sep-2024 SMC accepts bispecific antibody TECVAYLI®▼ (teclistamab) for eligible patients with relapsed and refractory multiple myeloma Johnson & Johnson
09-Sep-2024 Department of Immunology, Institute of Microbiology, Bulgarian Academy of Sciences and Enzolytics, Inc. Execute Three Year Agreement AccessWire
09-Sep-2024 Ankle & Foot Centers of America Gets Athletes Back on the Field AccessWire
09-Sep-2024 Medholdings Group Inc. Acquires MedSmart Wellness Centers AccessWire
09-Sep-2024 The Center for Immunology Science and Immunology Diagnostics Announce a Major Breakthrough Discovery: DNA-Based Proof of the Disease of Fibromyalgia Newswire
09-Sep-2024 Secarna Pharmaceuticals will present data at 6th Inflammasome Therapeutics Summit demonstrating the potential of ASOs to target the expression of NLRP3 Secarna Pharmaceuticals GmbH & Co. KG
09-Sep-2024 Registration Is Now Open For Tribe Public's Webinar Event "Diabetes, Obesity, GLP-1, & The MODD-1 Opportunity" Featuring Modular Medical CEO On Wednesday, September 11, 2024 AccessWire